Overview
A Phase II Study of Continuous Versus Syncopated Dosing of CC-5013 for the Treatment of Refractory Multiple Myeloma
Status:
Completed
Completed
Trial end date:
2006-10-01
2006-10-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
To evaluate the response rate, response duration, and survival of patients treated with CC-5013 in a chronic dosing schedule versus a syncopated dosing schedule.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Celgene CorporationTreatments:
Lenalidomide
Thalidomide
Criteria
- History of histologically documented multiple myeloma with relapsed or resistantdisease
- Pregnant or nursing women may not participate. Women of childbearing potential must
have a negative pregnancy documented within one week of registration. Women of
reproductive potential may not participate unless they have agreed to use an effective
contraceptive method.
- Signed written informed consent and willingness to meet follow-up schedule and study
procedure obligations